Fargas likely gone, page-48

m, Do you have any evidence that Prana has complied with the FDA's request of last year to submit evidence of safety to aid them in lifting the partial clinical hold? It is my opinion that many former shareholders including the institutions and funds have not returned due to the fact that the roadblock is in Prana's hands.

There have been many opportunities throughout the years for PBT2 to prove itself through the drug regulatory process. Prana has not been successful in convincing any regulators, not only the FDA, of the usefulness of PBT2 or any other product.

BTW it might serve better to not concentrate solely on Biogen and the amyloid beta theory as Prana's only competitor. There is much more current work progressing in the rest of the scientific world. That information is easily found in professional medical and business literature. It's changing daily.